• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    ARS Pharmaceuticals, Inc. - Common Stock (NQ:SPRY)

    9.000 -0.440 (-4.66%)
    Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about ARS Pharmaceuticals, Inc. - Common Stock

    < Previous 1 2 3 Next >
    News headline image
    ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray)
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray)
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    neffy® (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Real-World Evidence Supports Clinical Effectiveness of neffy® (epinephrine nasal spray) in Patients Experiencing Anaphylaxis
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals’ neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.